[November 07, 2012]

OPKO Health Announces Grant to Develop Tuberculosis Diagnostics Technology

OPKO Health, Inc. (NYSE: OPK) announced today that it was awarded a $1 million grant from the Bill & Melinda Gates Foundation to support the development of a diagnostic test to distinguish between latent tuberculosis and active tuberculosis utilizing OPKO's proprietary molecular diagnostics technology. Utilizing its proprietary technology, OPKO is developing simple blood tests to identify biomarkers for a wide variety of diseases, including neurodegenerative disorders and various malignancies.

About OPKO Health, Inc.

We are a multi-national biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large and rapidly growing medical markets by leveraging our discovery, development and commercialization expertise and our novel and proprietary technologies.

This press release contains "forward-looking statements," as hat term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding our ability to develop a diagnostic test that distinguishes between latent and active tuberculosis and other simple blood tests that identify biomarkers for a wide variety of diseases, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our filings with the Securities and Exchange Commission, as well as risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

[ Back To TMCnet.com's Homepage ]